Pantoxobe (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoxobe, is a proton pump inhibitor presented as an injectable solution for intravenous use. It reduces gastric acid secretion and is used to treat conditions such as erosive oesophagitis, gastric ulcer, and Zollinger‑Ellison syndrome in hospital settings.

GNH USA supplies Pantoxobe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Pantoxobe is indicated for several gastrointestinal disorders that involve excess acid production: - Erosive oesophagitis: promotes healing of the esophageal lining by reducing acid exposure. - Gastric ulcer: supports ulcer resolution through sustained acid suppression. - Duodenal ulcer: aids in ulcer healing by maintaining a low‑acid environment. - NSAID‑induced ulcer disease: mitigates ulcer risk associated with non‑steroidal anti‑inflammatory drugs. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid in this rare endocrine disorder. - Stress ulcer prophylaxis: prevents stress‑related gastric mucosal damage in critically‑ill patients.

Adverse reactions to Pantoxobe may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that are usually transient. - Nausea: feeling of sickness without vomiting. - Abdominal pain: discomfort in the stomach region. - Injection site reactions: redness, swelling, or mild pain at the IV site.

Serious or Rare Side Effects: - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Clostridioides difficile infection: persistent diarrhea with possible colitis. - Electrolyte disturbances: low magnesium or potassium levels. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress.

When using Pantoxobe, clinicians should consider several safety measures: - Renal impairment: adjust dosing or monitor renal function in patients with reduced kidney function. - Hepatic impairment: use with caution in moderate to severe liver disease. - Elderly patients: monitor for increased sensitivity to side effects. - Concomitant medications: review for potential drug‑drug interactions before initiating therapy. - Pregnancy and lactation: evaluate risk‑benefit ratio as safety data are limited. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoxobe can interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Ketoconazole: reduced absorption of the antifungal due to increased gastric pH. - Atazanavir: decreased plasma levels of the antiretroviral, compromising efficacy. - Clopidogrel: diminished activation of the antiplatelet, potentially lowering its effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values, requiring more frequent coagulation monitoring. - Digoxin: increased serum concentrations may occur, necessitating level checks. - Methotrexate: reduced renal clearance can raise toxicity risk.